Amgen Foundation pledges up to $5 million to Hurricane Maria relief efforts

AmgenAmgen (NASDAQ:AMGN) announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. The Foundation also has committed up to an additional $2 million for longer-term rebuilding efforts. Amgen is also activating its Staff Disaster Relief Fund to aid Amgen staff in Puerto Rico, including financial assistance for shelter, medical attention, clothing and other critical relief.

"Our thoughts are with our colleagues, their families and everyone impacted by the devastation in Puerto Rico. We are committed to assisting with the relief and rebuilding efforts for all those who call the island their home," said Cynthia M. Patton, chief compliance officer at Amgen and chair of the Amgen Foundation Board of Directors.

"This is a true humanitarian crisis impacting 3.5 million people on the island, including over 2,000 Amgen staff and their families. This commitment from the Amgen Foundation reflects our heartfelt concern for the community," said Esteban Santos, executive vice president of Operations at Amgen and member of the Amgen Foundation Board of Directors. "In addition, Amgen is working to ensure access to our medicines for patients in Puerto Rico and to returning our operations in Juncos to normal as quickly as possible."

The Amgen Foundation will also match donations made by Amgen staff around the globe who wish to contribute their own funds to the relief efforts resulting from Hurricanes Maria, Irma and Harvey, as well as the earthquakes in Mexico.

About the Amgen Foundation
The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated over $250 million to local, regional, and international nonprofit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars, Amgen Biotech Experience, and Amgen Teach.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

FDA awards 15 grants for clinical trials to stimul…

The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to...

A need for bananas? Dietary potassium regulates ca…

Bananas and avocados - foods that are rich in potassium - may help protect against pathogenic vascular calcification, also known as hardening of the arteries. University ...

Amgen and CytomX Therapeutics announce strategic c…

Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The co...

Roche launches NAVIFY Tumor Board solution to prov…

Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-...

Tagrisso granted breakthrough therapy designation …

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatm...

Pfizer launches novel programs to put important su…

Pfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer...

Novartis and UC Berkeley collaborate to tackle 'un…

Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pu...

Printed meds could reinvent pharmacies, drug resea…

A technology that can print pure, ultra-precise doses of drugs onto a wide variety of surfaces could one day enable on-site printing of custom-dosed medications at pharma...

Amgen and Simcere announce strategic collaboration…

Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group have announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. Th...

IDF and Novo Nordisk launch first-ever global surv…

To mark World Heart Day today, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigat...

FDA awards six grants for natural history studies …

The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to i...

Indian government needs to do more to tackle risin…

In India, the sale of antibiotics requiring the tightest control and regulation is rising the fastest, according to an analysis by researchers at Queen Mary University of...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]